PhRMA
7 data points extracted from 1 publication by this organisation.
Data points
7
Documents
1
Indicators
7
Regions
2
Publisher type
Industry association
Bibliography
Documents used
Every publication we have taken a number from, with the date we read it and the link status at that time.
| Document | Type | Published | Retrieved | Link | Data points |
|---|---|---|---|---|---|
| Research & Development Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 7 |
Every figure
Data points
Every figure taken from this organisation, grouped by indicator.
| Indicator | Region | Period | Value | Type | Full record |
|---|---|---|---|---|---|
| Approved immunotherapy drugs (multi-year total) | United States | 2010–2025 | 30 | actual | → |
| Average cost to develop a new medicine | Global | end of 2025 | 2.6 billion USD | estimate | → |
| Biopharmaceutical R&D expenditure (multi-year total) | United States | 2015–2024 | 900 billion USD | actual | → |
| Clinical development regulatory approval rate | United States | end of 2025 | 12% | estimate | → |
| Cumulative biopharmaceutical R&D expenditure | United States | 2000–2025 | 1 trillion USD | actual | → |
| Medicines in clinical development | Global | 2025 | 8,000 | estimate | → |
| Rare diseases treatment availability rate | Global | end of 2025 | 5% | estimate | → |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. Credit PhRMA as the original publisher; each record page carries its own citation.
PhRMA. Retrieved from StatOrigin: https://statorigin.org/sources/phrma
Keep exploring
Related
Industries using this source
Last verified 17 September 2026. Link status is rechecked weekly.